Memogain
Memogain (Gln-1062), a pro-drug, liberates galantamine on cleavage by a carboxyesterase in the brain. Memogain delivered intranasally may further circumvent side effects, allowing higher dosing compared to galantamine and avoid degradation by digestive tract carboxylesterases
General
Type : Derivative of Galanthamine,Alkaloid,Benzoate,Natural_modified,Benzazepin,Azepine
Chemical_Nomenclature : (4aS,6R,8aS)-3-methoxy-11-methyl-4a,5,9,10,11,12-hexahydro-6H-benzo[2,3]benzofuro[4,3-cd]azepin-6-yl benzoate
Canonical SMILES : CN1CCC23C=CC(CC2OC4=C(C=CC(=C34)C1)OC)OC(=O)C5=CC=CC=C5
InChI : InChI=1S\/C24H25NO4\/c1-25-13-12-24-11-10-18(28-23(26)16-6-4-3-5-7-16)14-20(24)29-22-19(27-2)9-8-17(15-25)21(22)24\/h3-11,18,20H,12-15H2,1-2H3\/t18-,20-,24-\/m0\/s1
InChIKey : JKVNJTYHRABHIY-WXVUKLJWSA-N
Other name(s) : SCHEMBL16885442,CS-6749,HY-101710,Gln-1062
MW : 391.46
Formula : C24H25NO4
CAS_number : 224169-27-1
PubChem : 44240142
UniChem : JKVNJTYHRABHIY-WXVUKLJWSA-N
IUPHAR :
Wikipedia :
Target
References (3)
| Title : First in human study with a prodrug of galantamine: Improved benefit-risk ratio? - Baakman_2016_Alzheimers.Dement.(N.Y)_2_13 |
| Author(s) : Baakman AC , t Hart E , Kay DG , Stevens J , Klaassen ES , Maelicke A , Groeneveld GJ |
| Ref : Alzheimers Dement (N Y) , 2 :13 , 2016 |
| Abstract : Baakman_2016_Alzheimers.Dement.(N.Y)_2_13 |
| ESTHER : Baakman_2016_Alzheimers.Dement.(N.Y)_2_13 |
| PubMedSearch : Baakman_2016_Alzheimers.Dement.(N.Y)_2_13 |
| PubMedID: 29067291 |
| Title : Nasal Application of the Galantamine Pro-drug Memogain Slows Down Plaque Deposition and Ameliorates Behavior in 5X Familial Alzheimer's Disease Mice - Bhattacharya_2015_J.Alzheimers.Dis_46_123 |
| Author(s) : Bhattacharya S , Maelicke A , Montag D |
| Ref : J Alzheimers Dis , 46 :123 , 2015 |
| Abstract : Bhattacharya_2015_J.Alzheimers.Dis_46_123 |
| ESTHER : Bhattacharya_2015_J.Alzheimers.Dis_46_123 |
| PubMedSearch : Bhattacharya_2015_J.Alzheimers.Dis_46_123 |
| PubMedID: 25720404 |
| Title : Memogain is a galantamine pro-drug having dramatically reduced adverse effects and enhanced efficacy - Maelicke_2010_J.Mol.Neurosci_40_135 |
| Author(s) : Maelicke A , Hoeffle-Maas A , Ludwig J , Maus A , Samochocki M , Jordis U , Koepke AK |
| Ref : Journal of Molecular Neuroscience , 40 :135 , 2010 |
| Abstract : Maelicke_2010_J.Mol.Neurosci_40_135 |
| ESTHER : Maelicke_2010_J.Mol.Neurosci_40_135 |
| PubMedSearch : Maelicke_2010_J.Mol.Neurosci_40_135 |
| PubMedID: 19669943 |